Unicycive Therapeutics (UNCY) Non Operating Interest Expenses (2020 - 2025)

Unicycive Therapeutics (UNCY) has reported Non Operating Interest Expenses for 6 consecutive years, with $27000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Interest Expenses rose 35.0% year-over-year to $27000.0; the trailing twelve-month figure through Dec 2025 stood at $70000.0 (down 1.41% YoY), and the FY2025 full-year result was $71000.0, changed 0.0% from the prior year.
• Non Operating Interest Expenses grew to $27000.0 in Q4 2025 per UNCY's latest filing, from $15000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $321000.0 in Q2 2021 and bottomed at $3000.0 in Q3 2022.
• Historically, Non Operating Interest Expenses has averaged $50352.9 across 5 years, with a median of $18000.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Non Operating Interest Expenses surged 15950.0% in 2021, then tumbled 94.55% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at $55000.0 in 2021, then sank by 94.55% to $3000.0 in 2022, then soared by 533.33% to $19000.0 in 2023, then climbed by 5.26% to $20000.0 in 2024, then soared by 35.0% to $27000.0 in 2025.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $27000.0, $15000.0, and $13000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.